United States · Platforms & data · Morningstar

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Published by Morningstar · United States 1 d ago

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

The Motley Fool

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Share

Also worth reading

Westinghouse Air Brake Technologies: 3 Key Takeaways for Long-Term Investors

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Kazia gains as Guggenheim is latest to initiate at Buy on lead asset

Medicare is a bargain. What America can’t afford is private health insurance.

Initial jobless claims highlight Thursday’s economic calendar

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge